A Phase 1/2 Study of Evofosfamide, a Hypoxia-Activated Prodrug With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1325
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Carfilzomib Monotherapy in Japanese Patients With Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

Cancer Science
Cancer ResearchMedicineOncology
2019English

Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib

Blood Cancer Journal
OncologyHematology
2015English

Retreatment With Bendamustine-Bortezomib-Dexamethasone in a Patient With Relapsed/Refractory Multiple Myeloma

Case Reports in Hematology
2016English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Phase 1 Study of the Protein Deubiquitinase Inhibitor VLX1570 in Patients With Relapsed and/or Refractory Multiple Myeloma

Investigational New Drugs
OncologyPharmacology
2020English

Atacicept in Relapsed/Refractory Multiple Myeloma or Active Waldenström's Macroglobulinemia: A Phase I Study

British Journal of Cancer
Cancer ResearchOncology
2009English

A Phase I Clinical Study of Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2017English

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Cancer
Cancer ResearchOncology
2016English

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

American Journal of Hematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy